Protagenic Therapeutics proposes up to US$5M placement for anxiety trial

An initial US$1.5 million would support preparations for a first U.S. anxiety trial as Protagenic Therapeutics, Inc. OTCMKTSPTIX announced a private placement on Wednesday. A further US$3.5 million depends on warrant exercises, bringing potential gross proceeds to US$5 million.

The Nov. 11 release describes financing from new and existing investors through common stock, pre-funded warrants and common warrants. Brookline Capital Markets, a division of Arcadia Securities, LLC, is the sole placement agent; fees and offering expenses will reduce the gross proceeds.

Protagenic is a small, New York-based clinical-stage biotechnology company developing peptide medicines for stress-related psychiatric disorders.

The OTCMKTSPTIX quote page showed US$0.49 at 3:55 p.m. EST on Nov. 10, before Wednesday's announcement. The company targets its first U.S. patient dosing in the second quarter of 2027, subject to FDA review.

Financing Terms Leave Dilution Unquantified

The US$5 million maximum in the Nov. 11 announcement includes proceeds conditional on full exercise of two series of milestone-linked warrants. The release does not identify those milestones, the exercise prices or the warrants' expiry dates.

It also omits the placement's issue price, security counts and expected closing date. Those omissions prevent calculation of the discount to the quoted share price, the increase in outstanding shares or existing shareholders' percentage dilution.

A separate Nov. 6 securities filing discloses a US$250,000 promissory note issued to Patness LLC on Nov. 4. Its principal becomes payable at the earlier of a qualifying equity financing or 180 days after issuance.

Under the Nov. 4 note, a qualifying financing means an equity capital raise of at least US$1 million in gross cash proceeds. The placement announcement does not discuss the note or state net proceeds after fees.

The stated uses are work needed for an investigational new drug application, initiation of the planned trial, working capital and general corporate purposes. The release gives no cash-runway estimate, and the company says it continues to seek additional capital.

Read more: PolyPid reports US$15.5M in liquidity ahead of FDA goal date

"Our plan, informed by FDA's feedback, is designed to establish the safety of our novel neuropeptide along with an early efficacy signal in patients with Generalized Anxiety Disorder," Protagenic president Bill Nichols Jr. said in the release.

First U.S. Dosing Targeted For 2027

PT00114 is an investigational synthetic analogue of a naturally occurring brain peptide thought to regulate stress responses. The proposed Phase 1/2a study would begin with ascending-dose cohorts assessing safety, tolerability and pharmacokinetics, followed by a cohort with generalized anxiety disorder.

That patient cohort would assess exploratory efficacy measures, including change from baseline on the Hamilton Anxiety Rating Scale. The announcement does not give planned enrolment, a control arm or a statistical threshold for efficacy.

According to the Nov. 11 development update, FDA feedback received in August identified no deficiencies precluding an application submission. Protagenic says it is incorporating the agency's requests through refined manufacturing specifications and expanded dose cohorts; that feedback is not authorization to begin the U.S. trial.

The company previously completed two Phase 1 studies outside the United States. It says the multiple-dose study found PT00114 well tolerated across studied doses, with no serious adverse events observed.

Read more: NRx Pharmaceuticals starts ketamine sales effort ahead of January shipments

The next targeted regulatory milestone is submission of the investigational new drug application in late first-quarter 2027. FDA review would precede the second-quarter dosing target; Protagenic expects topline safety data in the second half of 2027 and exploratory efficacy data in the first half of 2028.